hVIVO (LON:HVO) Stock Price Down 6.8% – What’s Next?

hVIVO plc (LON:HVO)’s share price fell 6.8% during mid-day trading on Thursday . The stock traded as low as GBX 19 ($0.24) and last traded at GBX 19.10 ($0.24). 2,518,262 shares traded hands during mid-day trading, a decline of 26% from the average session volume of 3,389,765 shares. The stock had previously closed at GBX 20.50 ($0.26).

hVIVO Stock Down 6.8 %

The company has a debt-to-equity ratio of 33.86, a quick ratio of 1.16 and a current ratio of 1.61. The company has a market capitalization of £129.95 million, a PE ratio of 636.67 and a beta of 0.97. The company’s fifty day moving average is GBX 23.58 and its 200-day moving average is GBX 26.77.

hVIVO Company Profile

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.